INTEGRA LIFESCIENCES HOLDINGS CORP Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
INTEGRA LIFESCIENCES HOLDINGS CORP (IART) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 4.09% for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-02-26
- INTEGRA LIFESCIENCES HOLDINGS CORP share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 4.09%, a 5.96% increase from fiscal 2023.
- INTEGRA LIFESCIENCES HOLDINGS CORP share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 3.86%, a 92.04% increase from fiscal 2022.
- INTEGRA LIFESCIENCES HOLDINGS CORP share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 2.01%, a 54.62% increase from fiscal 2021.
- INTEGRA LIFESCIENCES HOLDINGS CORP share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2021 was 1.30%, a 46.07% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|
| 2024-12-31 | 4.09% 10-K · filed 2026-02-26 |
| 2023-12-31 | 3.86% 10-K · filed 2026-02-26 |
| 2022-12-31 | 2.01% 10-K · filed 2025-02-25 |
| 2021-12-31 | 1.30% 10-K · filed 2024-02-28 |
| 2020-12-31 | 0.89% 10-K · filed 2023-02-22 |
| 2019-12-31 | 2.51% 10-K · filed 2022-02-24 |
| 2018-12-31 | 2.79% 10-K · filed 2021-02-23 |
| 2017-12-31 | 2.18% 10-K · filed 2020-02-21 |
| 2016-12-31 | 1.94% 10-K · filed 2019-02-26 |
| 2015-12-31 | 1.96% 10-K · filed 2018-03-01 |
| 2014-12-31 | 2.41% 10-K · filed 2017-02-23 |
| 2013-12-31 | 1.52% 10-K · filed 2016-02-26 |
| 2012-12-31 | 1.33% 10-K · filed 2015-02-27 |
| 2011-12-31 | 2.47% 8-K · filed 2014-06-20 |
| 2010-12-31 | 2.82% 10-K · filed 2013-02-26 |
| 2009-12-31 | 2.00% 10-K · filed 2012-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| PROCEPT BioRobotics Corp (PRCT) | United States | $1.001B | -11.77 |
| Beta Bionics, Inc. (BBNX) | United States | $0.979B | -9.66 |
| Alphatec Holdings, Inc. (ATEC) | United States | $1.531B | -12.14 |
| KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) | United States | $1.535B | -9.02 |
| SpyGlass Pharma, Inc. (SGP) | United States | $0.925B | |
| SI-BONE, Inc. (SIBN) | United States | $0.830B | -49.82 |
| MIMEDX GROUP, INC. (MDXG) | United States | $0.687B | 89.92 |